Cyclopharm Ltd (CYC)
Australian Securities Exchange · Australia · prices in AUD · close of 21 Oct 2026
Key indicators
| Last close | AUD 0.370 |
|---|---|
| 52-week range | 0.370 – 1.290 |
| Return, 1 month / 3 months | −22.9% / −33.9% |
| Return, 1 year / 3 years | −43.5% / −82.9% |
| Trend | Below its 200-day average |
| RSI (14) | 30 |
| Volatility (1 year) | 79.6% |
| Worst drawdown (1 year) | -69.9% |
| Average daily value traded | 0.03M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cyclopharm Ltd is an Australian medical technology company that develops and supplies products for nuclear medicine imaging. Its main product, Technegas, is a carbon-based aerosol that patients inhale so that clinicians can take pictures of lung ventilation and assess how well the lungs are working. The company serves hospitals and nuclear medicine departments, and its technology is used in the diagnosis of lung conditions such as pulmonary embolism. Cyclopharm is based in Australia.
The shares are listed on the Australian Securities Exchange in Australia under the code CYC, and the price on this page is in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cyclopharm Ltd (CYC) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.370 on 21 October 2026.
Its price-based Market X-Ray is 27 out of 100 (a weak price profile), ranking 1,478 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 43.5% and over the last three months it fell 33.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 14 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -44.6% | ||
| From 52-week high | -69.9% | ||
| Momentum | 22 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -33.9% | ||
| 6-month return | -48.6% | ||
| 12-month return, skipping the last month | -26.7% | ||
| Stability (higher is calmer) | 34 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 79.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -69.9% | ||
| Liquidity | 48 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M AUD | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −18.7% |
|---|---|
| 1 month | −22.9% |
| 3 months | −33.9% |
| 6 months | −48.6% |
| 1 year | −43.5% |
| 3 years | −82.9% |
| 5 years | −80.6% |
Signals
| 50-day / 200-day average | 0.478 / 0.668 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.023 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Sep 2023 | AUD 0.0050 |
| 27 Mar 2023 | AUD 0.0050 |
| 2 Sep 2022 | AUD 0.0050 |
| 4 Apr 2022 | AUD 0.0050 |
| 3 Sep 2021 | AUD 0.0050 |
| 1 Apr 2021 | AUD 0.0050 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.